Effect of Genital Herpes on Cervicovaginal HIV Shedding in Women Co-Infected with HIV AND HSV-2 in Tanzania
Open Access
- 13 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3), e59037
- https://doi.org/10.1371/journal.pone.0059037
Abstract
To compare the presence and quantity of cervicovaginal HIV among HIV seropositive women with clinical herpes, subclinical HSV-2 infection and without HSV-2 infection respectively; to evaluate the association between cervicovaginal HIV and HSV shedding; and identify factors associated with quantity of cervicovaginal HIV. Four groups of HIV seropositive adult female barworkers were identified and examined at three-monthly intervals between October 2000 and March 2003 in Mbeya, Tanzania: (1) 57 women at 70 clinic visits with clinical genital herpes; (2) 39 of the same women at 46 clinic visits when asymptomatic; (3) 55 HSV-2 seropositive women at 60 clinic visits who were never observed with herpetic lesions; (4) 18 HSV-2 seronegative women at 45 clinic visits. Associations of genital HIV shedding with HIV plasma viral load (PVL), herpetic lesions, HSV shedding and other factors were examined. Prevalence of detectable genital HIV RNA varied from 73% in HSV-2 seronegative women to 94% in women with herpetic lesions (geometric means 1634 vs 3339 copies/ml, p = 0.03). In paired specimens from HSV-2 positive women, genital HIV viral shedding was similar during symptomatic and asymptomatic visits. On multivariate regression, genital HIV RNA (log10 copies/mL) was closely associated with HIV PVL (β = 0.51 per log10 copies/ml increase, 95%CI:0.41–0.60, pβ = 0.24 per log10 copies/ml increase, 95% CI:0.16–0.32, pβ = −0.10, 95%CI:−0.28–0.08, p = 0.27). HIV PVL and HSV shedding were more important determinants of genital HIV than the presence of herpetic lesions. These data support a role of HSV-2 infection in enhancing HIV transmissibility.This publication has 39 references indexed in Scilit:
- Long‐Term Impact of Acyclovir Suppressive Therapy on Genital and Plasma HIV RNA in Tanzanian Women: A Randomized Controlled TrialThe Journal of Infectious Diseases, 2010
- Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialThe Lancet, 2010
- Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2The New England Journal of Medicine, 2010
- Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South AfricaAIDS, 2009
- Herpes Simplex Virus (HSV)–Suppressive Therapy Decreases Plasma and Genital HIV‐1 Levels in HSV‐2/HIV‐1 Coinfected Women: A Randomized, Placebo‐Controlled, Cross‐Over TrialThe Journal of Infectious Diseases, 2008
- Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivationThe Journal of Experimental Medicine, 2007
- Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in TanzaniaSexually Transmitted Infections, 2006
- Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, TanzaniaSexually Transmitted Infections, 2003
- Recent Herpes Simplex Virus Type 2 Infection and the Risk of Human Immunodeficiency Virus Type 1 Acquisition in IndiaThe Journal of Infectious Diseases, 2003
- Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.JCI Insight, 1997